Novo Nordisk NVO and Viking Therapeutics VKTX have emerged as notable players in the obesity space. A market leader in the GLP-1 space, Novo Nordisk markets its semaglutide drugs under brand names ...

Novo Nordisk shows strong fundamentals and long-term return potential despite valuation concerns and US pricing risks. Find ...

Top Alternatives to Ozempic That Are EffectiveReviewed by Dr. Craig Primack, MD, FACP, FAAP, FOMAOzempic is a medication ...

GLP-1 drugs like Ozempic and Zepbound are great at promoting weight loss, but they also cause folks to lose muscle along with ...

BOSTON, June 23, 2025 (GLOBE NEWSWIRE) -- DoseSpot, which delivers best-in-class e-prescribing, insurance verification and revenue cycle management solutions for healthcare providers, announced today ...

Over two percent of adult patients now take a GLP-1 drug to treat overweight or obesity, according to newly released FAIR Health data. Among all adult patients, the percentage who had an ...

The report found that just over 2% of adults in the U.S. took a GLP-1 to treat obesity or overweight in 2024, up from just 0.3% in 2019. This is a relative increase of 586.7%, according to the ...

Among all adults with a GLP-1 prescription, the percentage of those diagnosed with obesity or overweight but not Type 2 diabetes increased from 3.7% in 2019 to 16.5% in 2024. 3.

Wegovy and other GLP-1 obesity and blood sugar control drugs accounted for 17% of pharmacy benefits spending at CBIZ employer clients with self-funded health plans in 2024, up from 13% in 2023 ...

CHERRY HILL, N.J., May 27, 2025 (GLOBE NEWSWIRE) -- New data from digital marketing agency Sagapixel reveals that public interest in the term “GLP-1” has officially surpassed search volume for ...

For adults with diabetes and obesity, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are associated with a reduced risk for obesity-related cancer compared with dipeptidyl peptidase-4 (DPP ...

Among all adult patients prescribed a GLP-1 drug, the percentage who had an overweight or obesity diagnosis and no type 2 diabetes diagnosis increased from 3.7% in 2019 to 16.5% in 2024, a ...